Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression - Poll - MDSpire

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

  • By

  • Mindan Xing

  • Yi Lu

  • Yan Guo

  • Yantao Jiang

  • Hengqi Liu

  • Junjie Yu

  • Luyao Tong

  • Zhongyu Wang

  • Chao Li

  • Xing Chen

  • Wei Luo

  • July 2, 2026

  • 0 min

Share

Original Source(s)

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

  • by Mindan Xing, Yi Lu, Yan Guo, Yantao Jiang, Hengqi Liu, Junjie Yu, Luyao Tong, Zhongyu Wang, Chao Li, Xing Chen, Wei Luo

  • July 2, 2026

Related Content

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making

Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

The plasmacytoid dendritic cell paradox in cancer: impaired type I interferon responses in a nucleic acid–rich tumor microenvironment